Skip to main content

Table 3 Determination of residual TFV on a subset of returned gel applicators

From: Application of a composite measure of product adherence, protocol compliance, and semen exposure to a phase III microbicide HIV prevention trial

All applicators (n = 901)

Group

Number of applicators

Number of applicators with detectable TFV

1% TFV Gel

556

539 (97%)

Placebo

345

19 (5%)

Vaginally inserted 1% TFV gel

456

452 (99%)